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We investigated the influence of the activation state of
integrin a5b1 on its dependence on the PHSRN synergy
site for binding to RGD in fibronectin. K562 and MV3
cells lacked avb3 expression and adhered to fibronectin
through a5b1. Mel57 cells adhered through avb3 and
a5b1. A recombinant fibronectin polypeptide, contain-
ing five type III repeats from the central cell binding
domain 3Fn6–10, and a mutated polypeptide lacking the
synergy site were equally effective in promoting Mel57
adhesion. For K562 and MV3, the mutated polypeptide
was not or poorly active compared to the control
polypeptide. Expression of avb3 in MV3 induced strong
adhesion to the mutated polypeptide. TS2/16 stimula-
tory b1-integrin antibodies or Mn21 induced a5b1-medi-
ated adhesion of K562 and MV3 to GRGDSP. In the pres-
ence of TS2/16 or Mn21, a5b1-mediated MV3 adhesion to
the mutated polypeptide was equally strong as adhesion
to the control polypeptide. Mn21 or TS2/16 inducedweak
K562 binding to the mutated polypeptide, and in the
presence of a combination of phorbol 12-myristate 13-
acetate, Mn21, and TS2/16, a5b1-mediated K562 adhesion
to the mutated and control polypeptide was equally
strong. Our findings demonstrate that requirement for
the PHSRN synergy site for a5b1-mediated adhesion to
RGD in fibronectin depends on the activation state of
the integrin.
Fibronectin (Fn)1 is an extracellular matrix glycoprotein that
functions in cell adhesion and migration in wound healing,
embryonic development, and malignant transformation (1, 2).
The Fn molecule is composed of three types of repeating mod-
ules, termed type I, II, and III repeats (3), which are organized
into functional domains. Proteolytic cleavage yields several
fragments containing domains that promote cell adhesion, in-
cluding the carboxyl-terminal HepII domain (4), the alterna-
tively spliced type III connecting segment (5), and the central
cell binding domain (CCBD).
The CCBD consists of type III repeats, each containing ap-
proximately 90 amino acids (6). Cells bind to the CCBD via
receptors of the integrin family (7). Integrins are ab het-
erodimeric transmembrane molecules mediating cell-cell adhe-
sion and attachment of cells to the extracellular matrix (8).
Integrins that bind the CCBD include a3b1 (9), a5b1 (10, 11),
avb1 (12), avb3 (13), aIIbb3 (14, 15), and avb6 (16).
The Arg-Gly-Asp (RGD) sequence in the 10th type III repeat
(3Fn10) is the key attachment site for binding of these inte-
grins to the CCBD, as demonstrated by inhibition of cell adhe-
sion with synthetic RGD-containing peptides (17, 18). Further-
more, two synergistic regions in the CCBD besides RGD have
been identified that are required for cell adhesion through
aIIbb3 (19) and a5b1 (20–23). For a5b1 binding to Fn, the
synergy region in 3Fn9 is the most important of these two
regions (21), and recently, a short amino acid sequence Pro-
His-Ser-Arg-Asn (PHSRN) was identified in this repeat that
synergistically enhances the cell adhesion promoting activity of
the RGD sequence (24). This sequence is also present in an
11-amino acid integrin binding site from 3Fn9 that is recog-
nized by aIIbb3 (25).
Integrins do not always constitutively bind to their ligands
with high affinity. Integrin adhesiveness can be stimulated by
phorbol esters and other more physiologically relevant agonists
(8, 26). In addition, antibodies have been described to integrin
b1 (27–30), b2 (31), and b3 (32) subunits, which induce a high
affinity state of the integrins. Studies with stimulatory b1
antibodies on hematopoietic cells have demonstrated modula-
tion of binding to natural ligands (28–30), modulation of ligand
specificity (33), modulation of binding to different regions in
one ligand (34), and modulation of the minimal sequence of a
binding site required for adhesion (35).
In the present study, we have investigated the role of the
PHSRN synergy site in a5b1- and avb3-mediated cell adhesion
to the CCBD in Fn. We show that requirement for the PHSRN
synergy site for cell adhesion to the CCBD depends on the
integrins expressed and on the activity of the integrins
involved.
MATERIALS AND METHODS
Fibronectin, Fragments, and Peptides—Plasma Fn was purchased
from Sigma. A 120-kDa chymotryptic Fn fragment containing the
CCBD (36, 37) was purchased from Life Technologies, Inc. Synthetic
peptide Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) was obtained from the
Department of Organic Chemistry, Faculty of Science, University of
Nijmegen (The Netherlands) and covalently bound to bovine serum
albumin (BSA) as previously described (38).
Production of Recombinant Fibronectin Polypeptides—To avoid the
artifactual losses of adhesive activity known to result from adsorbing
short polypeptides on substrates (e.g. see Ref. 23), we used recombinant
Fn polypeptides containing five type III Fn repeats from 3Fn6 through
3Fn10. The 3Fn6–10 wild type expression construct was generated
based on the T7 phage promotor and a Fn cDNA fragment encoding Fn
type III repeat numbers 6–10 produced using the polymerase chain
reaction method (24); the PHSRN sequence was present in repeat 9 and
RGD in repeat 10 (Fig. 2A). The amino-terminal sequence of 3Fn6
starts immediately after an initiation codon for methionine. To create
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substitution mutants, two complementary oligonucleotides with appro-
priate sequences were synthesized, annealed, and then cloned between
the BamHI and EcoRI sites of 3Fn9. This yielded a mutated polypeptide
3Fn6–10(SPSDN) where the PHSRN sequence from 3Fn9 was substi-
tuted by SPSDN from 3Fn8 (Fig. 2, A and B).
Protein expression was induced by 1 mM isopropyl-1-thio-b-D-galac-
topyranoside treatment of Escherichia coli strain BL21 (DE3, pLysS)
containing the expression plasmid. The expressed recombinant
polypeptides were purified by sequential DEAE and hydroxyapatite
column chromatography. The polypeptide was eluted from a DEAE
column (DE52, Whatman) using a linear gradient of 0–0.5 M NaCl in 10
mM sodium phosphate (pH 7.4), 1 mM EDTA, 0.02% sodium azide,
applied to a hydroxyapatite column (Bio-Rad), and eluted using a linear
gradient from 5 mM sodium phosphate (pH 6.5), 0.4 mM EDTA, 0.02%
sodium azide to 250 mM sodium phosphate (pH 6.5), 0.4 mM EDTA,
0.02% sodium azide. The fractions with peak absorbance were evalu-
ated for purity by SDS-polyacrylamide gel electrophoresis, pooled, dia-
lyzed against phosphate-buffered saline without Ca21 or Mg21 and with
0.02% sodium azide, and stored at 280 °C.
Cell Lines and Culture Conditions—The human melanoma cell lines
used included Mel57 (39) and MV3 (40). The K562 erythroleukemic cell
line was provided by Dr. Nancy Hogg. All cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Flow, Irvine, United
Kingdom) supplemented with 10% fetal calf serum, penicillin, and
streptomycin.
Antibodies—Anti-integrin antibodies included P1B5 anti-a3 (41),
purchased from Telios Pharmaceuticals Inc. (San Diego); HP2/1 anti-a4
(42), provided by Dr. Francisco Sanchez-Madrid; NKI-Sam1 anti-a5
(30), provided by Dr. Carl Figdor; 4B4 anti-b1 (43), purchased from
Coulter Immunology (Hialeah, FL); AJ2 anti-b1 (44), provided by Dr.
Eberhard Klein; C17 anti-b3 (45), provided by Dr. Arnoud Sonnenberg;
A109 polyclonal anti-av (46), purchased from Life Technologies, Inc.;
10E5 anti-aIIb (47), provided by Dr. Barry Coller; and LM142 anti-av
and LM609 anti-avb3 (48), provided by Dr. David Cheresh. The stim-
ulatory anti-integrin b1 mAbs were 8A2 (29), provided by Dr. Nicholas
Kovach, and TS2/16 (49), provided by Dr. Francisco Sanchez-Madrid.
Cell Adhesion—Cell adhesion assays were performed as previously
described (50). In short, polystyrene microtiter plates (Greiner, Alphen
a/d Rijn, The Netherlands) were coated overnight with the appropriate
adhesive ligands and blocked for 1 h at 37 °C with DMEM containing
0.5% (w/v) BSA. Subsequently, 1 3 104 51Cr-labeled cells in 50 ml of
DMEM/BSA were added to the wells and incubated for 30 min at 37 °C
in 5% CO2. Unbound cells were removed by washing with DMEM/BSA,
bound cells were lysed by detergent, and radioactivity of the lysate was
measured in a gamma counter. Results are presented as the mean
percentage of cell binding from triplicate wells. For induction of adhe-
sion, radiolabeled cells were preincubated with TS2/16 or 8A2 mAbs for
30 min at 4 °C before seeding in the wells or 1 mM MnCl2; or, 100 ng/ml
phorbol 12-myristate 13-acetate (PMA) was added to the cells prior to
seeding in the wells. For antibody inhibition studies, cells were prein-
cubated with the appropriate mAbs for 30 min at 4 °C before seeding
into the wells.
Flow Cytometry—Cells were incubated with mAbs in phosphate-
buffered saline containing 0.5% (w/v) BSA and 0.02% (w/v) sodium
azide for 30 min at 4 °C. After washing with phosphate-buffered saline/
BSA/azide, the cells were incubated with fluorescein-isothyocyanate-
labeled F(ab9)2 fragments of rabbit anti-mouse Ig antibodies (Dako,
Glostrup, Denmark) for 30 min at 4 °C. After washing, fluorescence was
measured on an Epics Elite flow cytometer (Coulter, Mijdrecht, The
Netherlands).
Transfection—The full-length cDNA for the integrin b3 subunit (51),
a kind gift from Dr. Erkki Ruoslahti, was cloned in the polylinker of the
mammalian expression vector pBJ1neo (52), kindly provided by Dr.
Rene´ de Waal-Malefijt. 20 mg of this construct was used for stable
transfection of MV3 cells according to the calcium phosphate precipita-
tion method (53), using the calcium phosphate transfection system (Life
Technologies, Inc.). After 48 h, stably transfected cells were selected by
culturing in the presence of 1 mg/ml G418 (Life Technologies, Inc.) for
2 weeks. Cell populations were enriched for avb3 expression by cell
sorting in an Epics Elite flow cytometer using LM609 mAbs. After three
cycles of sorting, transfected cell lines contained .95% avb3 positive
cells. Cells were maintained in culture in medium containing 200 mg/ml
G418 and were regularly monitored for avb3 expression.
RESULTS
K562, MV3, and Mel57 Differentially Adhere to the
CCBD—We investigated adhesion of K562 human erythroleu-
kemic cells and MV3 and Mel57 human melanoma cells to the
CCBD. Of the integrins known to be involved in adhesion to Fn,
FIG. 1. Inhibition of adhesion to Fn120 kDa with integrin
mAbs. Cells were allowed to adhere to wells coated with 20 mg/ml of a
120-kDa fragment of Fn (Fn120 kDa) in the absence (no) or in the
presence of inhibitory mAbs to integrin subunits as indicated. Adhesion
to BSA was less than 5%. One representative experiment of four is
shown.
FIG. 2. Recombinant FN polypeptides. A, schematic representa-
tion of a recombinant Fn polypeptide 3Fn6–10 consisting of five type III
Fn repeats from 3Fn6 through 3Fn10 and of a mutated Fn polypeptide
3Fn6–10(SPSDN) where the region containing PHSRN in 3Fn9 has
been substituted by the corresponding region from 3Fn8 (hatched bar).
B, in 3Fn6–10(SPSDN), 16 amino acid residues from 3Fn9 were sub-
stituted with the corresponding residues from 3Fn8 to disrupt the
PHSRN site in 3Fn9. Boxed sequences are from 3Fn6–10(SPSDN). The
region with italicized nucleotides differs from the original sequence in
3Fn8 for technical reasons to alter restriction sites, but this does not
alter the amino acid sequence.
TABLE I
Fibronectin-binding integrins on K562, MV3, and Mel57 cells
Mean fluorescence
C a3 a4 a5 av aIIb b1 avb3
K562 4 4 4 46 7 3 52 3
MV3 4 69 31 62 13 3 107 2
Mel57 3 41 17 23 33 3 33 41
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K562 exclusively expressed a5b1 (Table I). MV3 and Mel57
expressed a3b1, a4b1, and a5b1. In addition, Mel57 but not
MV3 expressed avb3. MV3 and Mel57 expressed other av
integrins including avb5 (54) and possibly avb1 that may bind
to Fn.
To exclude influences from domains outside the CCBD that
are known to have cell adhesive activity (HepII, IIICS), we used
a 120-kDa Fn fragment that lacks the heparin-binding domain
and the V region but includes the CCBD. K562 adhered weakly
to Fn120 kDa, whereas MV3 and Mel57 both adhered strongly
(Fig. 1). As expected from the surface expression data, adhesion
of K562 was completely blocked by mAbs to a5 or b1. Even
though MV3 expressed several Fn-binding integrins, adhesion
was fully blocked by mAbs to a5, whereas mAbs to a3 or a4 or
polyclonal anti-av had no effect. Adhesion of Mel57 was inhib-
ited approximately 35% by mAbs to a5 or b1 and about 50% by
FIG. 3. Adhesion to recombinant Fn polypeptides. K562, MV3, or Mel57 cells were allowed to adhere to wells coated with increasing
concentrations of 3Fn6–10(SPSDN) (dotted line) or 3Fn6–10 (line) as indicated. Adhesion to 0.1 mg/ml BSA was less than 4%. One representative
experiment of four is shown.
FIG. 4. Expression of avb3 on MV3 induces adhesion to 3Fn6–10(SPSDN). A, MV3 cells were untransfected (dotted line), transfected with
pBJ1neo alone (thin line), or transfected with pBJ1neo including integrin b3 cDNA followed by sorting with LM609 anti-avb3 mAbs (thick line).
Shown is the relative fluorescence after incubation with LM609 and a fluorescein-isothyocyanate-labeled second antibody. B, MV3neo or MV3-b3
cells were allowed to adhere to wells coated with increasing concentrations of 3Fn6–10(SPSDN) (dotted line) or 3Fn6–10 (line) as indicated. Filled
bars represent remaining adhesion to wells coated with 32 mg/ml 3Fn6–10(SPSDN) in the presence of inhibitory anti-integrin mAbs as indicated.
Adhesion to BSA was less than 3%. One representative experiment of three is shown.
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mAbs to b3 or avb3 or by polyclonal av. The combination of
mAbs to a5 and avb3 completely blocked adhesion of Mel57.
Thus, K562 adheres weakly to the CCBD through a5b1, MV3
binds strongly through a5b1, and Mel57 binds strongly
through a5b1 and avb3.
K562 and MV3 Require the PHSRN Synergy Site, Whereas
for Mel57 RGD Is Sufficient—To study the mechanism of bind-
ing of these cells to the CCBD, we used a recombinant Fn
polypeptide containing 3Fn6–3Fn10 and a mutated polypep-
tide lacking the recently described PHSRN synergy site (24)
(Fig. 2). As shown in Fig. 3, K562 did not adhere to the mutated
polypeptide and weakly to the control polypeptide. Only very
low adhesion of MV3 cells was observed to the mutated
polypeptide, whereas adhesion of MV3 to the control polypep-
tide was five times higher. In contrast, Mel57 cells adhered
strongly to both polypeptides. To investigate if this difference
was due to differential expression of avb3, we transfected MV3
cells with b3 cDNA, resulting in avb3 surface expression (Fig.
4A), and used these cells in adhesion assays. Expression of
avb3 provided MV3 cells with the capacity to adhere to
GRGDSP (not shown) and to the mutated polypeptide, and this
adhesion could be inhibited by C17 anti-b3 mAbs (Fig. 4B). A
similar level of inhibition was found with LM609 anti-avb3
(not shown).
From these results, we conclude that the differential require-
ment for the PHSRN synergy site for adhesion to RGD in the
CCBD of MV3 versus Mel57 is due to the different binding
mechanisms of a5b1 versus avb3.
Stimulation of a5b1-mediated RGD Binding with b1 mAbs,
PMA, and Manganese—The fact that K562 did not adhere to
the mutated polypeptide whereas MV3 did to a low extent (Fig.
3), even though both cell lines used a5b1, suggested that bind-
ing of a5b1 to RGD in 3Fn10 might depend on the activation
state of the integrin. To investigate this, we treated both cell
lines with 8A2 and TS2/16 stimulatory b1 mAbs, with Mn21, or
with PMA prior to using them in adhesion assays to a GRGDSP
peptide. PMA had no effect, 8A2 and TS2/16 induced weak
adhesion of K562 to GRGDSP, and treatment of MV3 cells with
these mAbs resulted in 25% adhesion to GRGDSP (Fig. 5A). A
control b1-integrin mAb AJ2 had no effect (not shown). The
strong binding of Mel57 was not enhanced by 8A2 or TS2/16.
Mn21 was less effective for K562 but induced adhesion of MV3
cells up to 35%. We performed adhesion inhibition assays to
examine whether the effect of 8A2 and TS2/16 was due to
activation of a5b1 or to the recruitment of other integrins.
Induced adhesion of K562 to GRGDSP in the presence of 8A2
(Fig. 5B) or TS2/16 (not shown) was blocked by mAbs to a5 and
not by any of the other mAbs. In addition, even though 8A2 and
TS2/16 may activate a3b1, a4b1, a5b1, and possibly avb1 on
MV3 cells, induced adhesion of MV3 to GRGDSP was com-
pletely blocked by mAbs to a5, whereas mAbs to a3, a4, and av
had no effect (Fig. 5B). The fact that the 4B4 anti-b1 mAb did
not inhibit adhesion in the presence of 8A2 is in line with the
report that activating and inhibiting antibodies share a com-
mon epitope on the b1 subunit (55).
Thus, the strength of a5b1 binding to RGD can be increased
by Mn21 and by activating b1 antibodies.
Requirement for the PHSRN Synergy Site Depends on the
Activation State of a5b1—As stimulatory b1 mAbs and Mn21
induced a5b1-mediated adhesion to GRGDSP, we hypothesized
that the activation state of a5b1 determines the requirement
for the PHSRN synergy site for cell adhesion to the CCBD.
Therefore, we treated K562 and MV3 cells with PMA, TS2/16,
or Mn21 and allowed them to adhere to the mutated and
control Fn polypeptides. TS2/16 and, to a lesser extent, Mn21
induced adhesion of K562 cells to the mutated polypeptide and
enhanced adhesion to the control polypeptide (Fig. 6). PMA
enhanced adhesion of K562 cells to the control polypeptide but
had no effect on adhesion to the mutated polypeptide. For MV3
cells, no effect of PMA was observed, but the low adhesion to
the mutated polypeptide was enhanced 5-fold by TS2/16 and
Mn21, resulting in a level of adhesion that was similar to that
observed with the fully active control polypeptide.
The fact that in the presence of TS2/16 or Mn21 no difference
was observed between the mutated and control polypeptide
regarding adhesion of MV3 cells, whereas for K562 the mu-
tated polypeptide was still poorly active, could suggest 1) that
stimulation of MV3 cells resulted in recruitment of other RGD-
binding integrins or 2) that a5b1 on K562 cells was not maxi-
mally activated by these agents. To exclude possibility 1, we
used mAbs to a3, a4, a5, av, b1, b3, avb3, or the combination
of these mAbs in the absence of anti-a5 for inhibition of TS2/
16-stimulated adhesion of MV3 cells to the mutated polypep-
FIG. 5. Stimulation of a5b1-mediated adhesion to GRGDSP. A,
Cells were incubated in the absence (no) or in the presence of PMA, 8A2
or TS2/16 stimulatory b1 mAbs, or manganese (Mn) and allowed to
adhere to wells coated with 20 mg/ml BSA-GRGDSP. B, cells that had
been previously incubated in the absence (x) or in the presence of 8A2
stimulatory b1 mAbs (8A2) were incubated in the absence (no) or in the
presence of inhibitory anti-integrin mAbs as indicated and allowed to
adhere to wells coated with 20 mg/ml BSA-GRGDSP. Adhesion to BSA
was less than 5%. One representative experiment of three is shown.
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tide. Stimulated adhesion was blocked by the anti-a5 mAb and
not by any of the other mAbs or their combination (Fig. 7),
suggesting that induction of adhesion to the mutated polypep-
tide of MV3 by TS2/16 was due to activation of a5b1 and not to
recruitment of other integrins.
To investigate possibility 2, we incubated K562 cells with
PMA, TS2/16, or Mn21 and the various combinations and al-
lowed the cells to adhere to the mutated and control polypep-
tide. In the presence of the combination of TS2/16 and Mn21,
adhesion to the mutated polypeptide was more than half the
level of adhesion to the control polypeptide (Fig. 8). PMA had
no effect by itself on adhesion to the mutated polypeptide but
enhanced adhesion to the control polypeptide more than 2-fold.
Finally, in the presence of the combination of PMA, TS2/16,
and Mn21, the control and the mutated polypeptide were
equally effective in promoting adhesion of K562 cells. This
adhesion was blocked by a5 mAbs (not shown).
From these results, we conclude that requirement of the
PHSRN synergy site for a5b1-mediated adhesion to RGD in the
CCBD depends on the activation state of a5b1.
DISCUSSION
In line with earlier reports, we find that avb3 does not
require the PHSRN site. We base this conclusion on 2 obser-
vations. First, Mel57 cells express avb3 and adhere equally
well to all molecules tested containing RGD, i.e. GRGDSP,
the mutated polypeptide lacking the synergy site 3Fn6–
10(SPSDN), the control polypeptide 3Fn6–10, and Fn120 kDa.
Second, the avb3 negative MV3 cells do not adhere to RGD-
containing ligands that lack the PHSRN site, and transfection
with b3 cDNA resulting in avb3 surface expression leads to
binding of these cells to GRGDSP and 3Fn6–10(SPSDN).
These findings confirm and extend the observations that
avb3 can be retained on an RGD column (56) whereas a5b1
cannot (11). Furthermore, these data are in agreement with the
recent report that av- and a3- but not a5-containing integrins
are bound by a column containing a Fn fragment lacking the
synergy region (57). Similarly, it has been reported that aIIbb3
but not avb3 binding to Fn can be inhibited by an 11-amino
acid peptide from 3Fn9 that also contains the PHSRN sequence
(25). Thus, RGD is sufficient for binding to Fn through avb3,
FIG. 6. Stimulation of adhesion to
recombinant Fn polypeptides. Cells
were incubated in the absence (v) or in
the presence of PMA (*), TS2/16 (), or
manganese () and allowed to adhere to
wells coated with increasing concentra-
tions of 3Fn6–10(SPSDN) (dotted line) or
3Fn6–10 (line) as indicated. Adhesion to
BSA was less then 4%. One experiment of
three is shown.
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whereas a5b1 and aIIbb3 require the synergy region for effi-
cient binding to Fn (24, 25).
Parenthetically, it has been reported that cross-talk between
avb3 and a5b1 can occur (58, 59). Therefore, the induced ad-
hesion to 3Fn6–10(SPSDN) upon expression of avb3 in MV3
cells did not necessarily have to be due to avb3-mediated ad-
hesion. Even though Blystone et al. (59) show that avb3 regu-
lates only a5b1-mediated phagocytosis, in our system avb3
might influence a5b1-mediated adhesion. Ligation of avb3
with LM609 mAbs might induce a signal that inhibits a5b1. To
exclude this possibility, we used C17 anti-b3 for adhesion in-
hibition assays. The fact that these mAbs inhibit adhesion of
b3-transfected MV3 cells to 3Fn6–10(SPSDN) suggests that
direct binding through avb3 rather than signaling to a5b1 is
involved.
The major conclusion from this study is that the requirement
for the PHSRN synergy site for a5b1-mediated adhesion to the
CCBD depends on the activation state of a5b1. This is based on
three findings. First, stimulation of K562 cells that express
only a5b1, with Mn21 or stimulatory b1-integrin mAbs, in-
duces adhesion to GRGDSP and 3Fn6–10(SPSDN). Second, in
the presence of the combination of PMA, TS2/16, and Mn21, the
mutated and control polypeptide are equally effective in pro-
moting K562 cell adhesion. Third, treatment of MV3 cells with
these agents induces adhesion to GRGDSP and enhances ad-
hesion to 3Fn6–10(SPSDN) to the level of adhesion to 3Fn6–
10, and this effect is completely blocked by antibodies to a5 but
not by mAbs to a3, a4, or av or the combination.
Even though the avb3-negative K562 and MV3 cells express
similar levels of a5b1, they differ dramatically in binding to
Fn120 kDa through this receptor. The view of cell type-specific
regulation of a5b1 affinity proposed by O’Toole et al. (60) sug-
gests that the default low affinity state of the integrin as
observed in K562 is switched to a high affinity state in MV3. As
a result, MV3 but not K562 cells bind strongly to Fn120 kDa.
Our finding that K562 cells bind poorly to Fn120 kDa and that
8A2 increases that adhesion two to three times is in line with
earlier findings (61). As expected, Mn21 and stimulatory b1
mAbs do not affect the strong adhesion of MV3 to Fn120 kDa.
However, our findings demonstrate that these agents do in fact
alter the avidity of a5b1 in MV3 cells but that this change can
only be observed in the absence of the PHSRN synergy site.
One interpretation of these findings is that intracellular factors
(induced by PMA for K562 and factors already present in MV3)
can increase the affinity of a5b1 to a level that RGD is recog-
nized in the Fn molecule and that additional extracellular
events are required for the final activation of a5b1, leading to
full adhesion to RGD in Fn. The synergy site could be involved
in the last step by locking the RGD site in the a5b1 binding
pocket, and in the presence of TS2/16 or Mn21 that last step
seems to be no longer required. Our finding that PMA enhances
K562 adhesion to the control polypeptide, whereas by itself it
has no effect on adhesion to the mutated polypeptide, is in line
with this idea. Furthermore, the fact that K562 cells in the
presence of TS2/16 bind strongly to the control polypeptide
without the need for PMA demonstrates that optimal extracel-
lular stimulation (the synergy site plus stimulatory b1 mAbs)
can abbrogate the need for intracellular activation (PMA).
It is of interest that comparable observations have been
reported for a4b1 (35). Even though Jurkat and Ramos cells
express an active form of a4b1 in the sense that they are
capable of binding to the CS1 domain of Fn, they only bind to a
peptide containing the EILDV recognition sequence from CS1
in the presence of stimulatory b1 mAbs. The authors suggest
that sequences may be present in the NH2-terminal portion of
CS1 that strengthen a4b1 binding to EILDV, although none
have yet been identified. Thus, the presence of sites that syn-
ergistically enhance binding of integrins to their recognition
sequence might be a general mechanism, and activation by
stimulatory b1 mAbs and Mn21 may bypass the dependence on
such sites. Our report, however, provides the first example of
substitution of the function of a well characterized synergy site
by agents that activate the integrins involved.
For leukocytes, stimulatory b1 mAbs also increase the affin-
ity of a4b1 for CS1 (35, 62) and for VCAM-1 (29), and they can
even induce a4b1 binding to the RGDS sequence (34). MV3
cells adhere to CS1 and tumor necrosis factor a-stimulated
endothelial cells in the absence of stimuli (not shown), indicat-
ing the expression of active a4b1 on these cells. For MV3 cells
in the absence or presence of stimuli, we do not observe any
inhibition of binding to the CCBD with HP2/1 anti-a4 mAbs,
whereas these mAbs inhibit binding to CS1 (not shown). Thus,
the reported recognition of RGD by stimulated a4b1 does not
play a role in our assay. This difference may be explained by
the fact that Ramos cells, as used by Sanchez-Aparicio et al.
(34), do not express a5b1. In MV3, the effect of TS2/16 on a4b1
FIG. 7. Inhibition of stimulated adhesion of MV3 to 3Fn6–
10(SPSDN) with integrin mAbs. MV3 cells were incubated in the
absence or in the presence of TS2/16 and allowed to adhere to wells
coated with 32 mg/ml 3Fn6–10(SPSDN). Inhibitory mAbs to integrin
subunits were added as indicated. Adhesion to BSA was less then 3%.
One experiment of three is shown.
FIG. 8. Stimulation of adhesion of K562 to recombinant Fn
polypeptides. K562 cells were incubated in the absence or in the
presence of various combinations of PMA, TS2/16, and Mn21 as indi-
cated and allowed to adhere to wells coated with 32 mg/ml 3Fn6–
10(SPSDN) (dotted bars) or 3Fn6–10 (filled bars). Adhesion to BSA was
less then 4%. One experiment of three is shown.
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may be masked by the binding to RGD through a5b1. Alterna-
tively, as previously reported (63), stimulatory b1 mAbs may
selectively activate a5b1 while leaving a4b1 unaffected.
A possible interpretation of our findings may be that the
PHSRN synergy site binds to the same epitope as recognized by
the stimulatory b1 mAbs. It has been previously suggested that
the epitope where these mAbs bind may physically interact
with extracellular proteins (55). However, the fact that binding
of K562 to 3Fn6–10 can be enhanced in the presence of 8A2 or
TS2/16 when PMA is absent indicates that the synergy site and
stimulatory mAbs can have additional combined stimulatory
effects. Therefore, these data seem to support a model where
the synergy site and stimulatory mAbs have different binding
sites on a5b1. This is in agreement with the recent report that
the mechanism of binding of integrin a5b1 to Fn seems to be
through binding of the a5 subunit to the synergystic regions
and of the b1 subunit to RGD (64).
In conclusion, our data demonstrate that a5b1 but not avb3
requires the PHSRN synergy site for cell adhesion to RGD in
the CCBD of Fn but that induction of a high affinity state of
a5b1 with PMA, stimulatory mAbs, and/or Mn21 abrogates
this dependence on the PHSRN sequence.
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